AbbVie Inc. (ABBV)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 153.13 |
| Open | 153.64 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1300 |
| Day's range | 151.37 - 153.83 |
| 52-week range | 130.96 - 168.11 |
| Volume | |
| Avg. volume | 4,743,708 |
| Market cap | 268.729B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 31.33 |
| EPS (TTM) | 4.86 |
| Earnings date | 26 Oct 2023 - 30 Oct 2023 |
| Forward dividend & yield | 5.92 (3.85%) |
| Ex-dividend date | 12 Oct 2023 |
| 1y target est | 169.61 |
ZacksTop Analyst Reports for Oracle, AbbVie & Lowe's
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), AbbVie Inc. (ABBV) and Lowe's Companies, Inc. (LOW).
ZacksIs It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ZacksAbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
© 2023 Yahoo. All rights reserved.
